Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Galili, U.
Right arrow Articles by Anaraki, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Galili, U.
Right arrow Articles by Anaraki, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Glycobiology vol 5 no 8 pp. 775-782, 1995
© 1995

research-article

{alpha}-Galactosyl (Gal{alpha}1-3Galß1-4GlcNAc-R) epitopes on human cells: synthesis of the epitope on human red cells by recombinant primate {alpha}1,3galactosyltransferase expressed in E.coli

Uri Galili and Farvardin Anaraki

Department of Microbiology and Immunology, The Medical College of Pennsylvania 2900 Queen Lane, Philadelphia, PA 19129, USA

Received on June 12, 1995; revised on July 25, 1995; accepted on July 27, 1995

Developing methods for in vitro synthesis of the carbohydrate structure Gal{alpha}1-3Galß1-4GlcNAc-R (termed the {alpha}-galactosyl epitope) on human tumour cells may be of potential clinical significance in cancer immunotherapy. Tumour vaccines with this epitope would be opsonized in vivo by the natural anti-Gal antibody, which is present in large amounts in humans, and which interacts specifically with {alpha}-galactosyl epitopes. Binding of anti-Gal to {alpha}-galactosyl epitopes on tumour cell membranes is likely to increase uptake of the cell membranes by antigen-presenting cells, such as macro-phages, via the adhesion of the Fc portion of anti-Gal to Fc receptors on these cells. This, in turn, may increase processing and presentation of tumour-associated antigens by antigen-presenting cells, and induce an effective immune response against tumour cells with these antigens. The present study describes a method for the synthesis of {alpha}-galactosyl epitopes on human cells (red cells used as a model) by recombinant {alpha}1,3galactosyltransferase (rec {alpha}1,3GT) expressed in bacteria. Escherichia coli was transformed with cDNA of the luminal portion of New World monkey rec {alpha}1,3GT linked to six histidines (His)6 at the N-terminus. The enzyme produced by the bacteria was isolated from bacterial lysates on a nickel-Sepharose column and eluted with imidazole. This recombinant enzyme displayed acceptor specificity similar to that of rec {alpha}1,3GT produced in COS cells. Red cells were pre-treated with sialidase for exposure of N-acetyllactosamine acceptors, then subjected to rec {alpha}1,3GT activity. This enzyme synthesized at least 4 x 104 {alpha}-galactosyl epitopes/red cell. These epitopes were found to be accessible for binding of anti-Gal, as well as Bandeiraea simplicifolia IB4 lectin. It is argued that the method presented can be used for the synthesis of {alpha}-galactosyl epitopes on membranes of autologous tumour vaccines in humans.

{alpha}1,3galactosyltransferase recombinant glycosyltrans-ferase red cell antigens tumour vaccine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 GlycobiologyHome page
L. Deriy, Z.-c. Chen, G.-P. Gao, and U. Galili
Expression of {alpha}-gal epitopes on HeLa cells transduced with adenovirus containing {alpha}1,3galactosyltransferase cDNA
Glycobiology, February 1, 2002; 12(2): 135 - 144.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.